Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study published today in the American Journal of Human Genetics.
The FDA has approved a new pre-analytical instrument that provides an integrated primary tube handling solution for Roches widely adopted automated molecular testing platform.
A new study released by Geisinger Health System researchers hopes to identify better screening and treatment options for the condition.
Clinical and Laboratory Standards Institute announces the webinar “Verification of AST Methods for the Implementation of the Carbapenem and Cephalosporin Breakpoints.”
The two organizations established the only on-site hospital laboratory in the country utilizing the diagnostic technology called TEM-PCR.
Its inventors say the microdissection device is an effective and reasonably priced method for removing tissue samples from microscope slides.
On March 15, genetic data from approximately 13,000 individuals were posted to dbGAP, the NIH’s online genetics database.
Siemens Healthcare Diagnostics is showcasing its portfolio of infectious disease testing capabilities at the 22nd ECCMID in London from March 31 to April 3.
Five-year follow-up data from the RASTER observational study indicates that Agendia’s MammaPrint prognostic assay for breast cancer can help reduce adjuvant chemotherapy by 20% in patients deemed “Low Risk.”
Clearbridge BioMedics has achieved ISO13485 certification for the development of cell-based in-vitro diagnostic devices and recently launched its ClearCell System, for the cancer research market.